{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:03:04Z","timestamp":1771340584383,"version":"3.50.1"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02075-w","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:09:56Z","timestamp":1771229396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress on the correlation between OPN and immune escape of gastric cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Fanjie","family":"Qu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"6","key":"2075_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ejca.2010.02.013","volume":"46","author":"AE Dassen","year":"2010","unstructured":"Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 2010;46(6):1101\u201310. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.013.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2075_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2217\/imt-2021-0103","volume":"14","author":"C Kole","year":"2022","unstructured":"Kole C, Charalampakis N, Tsakatikas S, Kouris NI, Papaxoinis G, et al. Immunotherapy for gastric cancer: a 2021 update. Immunotherapy. 2022;14(1):41\u201364. https:\/\/doi.org\/10.2217\/imt-2021-0103.","journal-title":"Immunotherapy"},{"issue":"10294","key":"2075_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"7903","key":"2075_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138. https:\/\/doi.org\/10.1038\/s41586-022-04508-4.","journal-title":"Nature"},{"issue":"2","key":"2075_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4):a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2075_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407\u201315. https:\/\/doi.org\/10.1007\/s10120-016-0631-3.","journal-title":"Gastric Cancer"},{"issue":"9","key":"2075_CR7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358. https:\/\/doi.org\/10.1038\/s41591-018-0101-z.","journal-title":"Nat Med"},{"issue":"4","key":"2075_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.21.01862","volume":"40","author":"JJ Zhao","year":"2022","unstructured":"Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, et al. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392\u2013402. https:\/\/doi.org\/10.1200\/JCO.21.01862.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2075_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2075_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1172\/JCI121266","volume":"129","author":"J Wei","year":"2019","unstructured":"Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019;129(1):137\u201349. https:\/\/doi.org\/10.1172\/JCI121266.","journal-title":"J Clin Invest"},{"issue":"9","key":"2075_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340. https:\/\/doi.org\/10.1038\/s41571-020-0363-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2075_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002624","volume":"9","author":"C Lu","year":"2021","unstructured":"Lu C, Liu Z, Klement JD, Yang D, Merting AD, et al. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 2021;9(7):e002624. https:\/\/doi.org\/10.1136\/jitc-2021-002624.","journal-title":"J Immunother Cancer"},{"key":"2075_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155.","journal-title":"Annu Rev Immunol"},{"key":"2075_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016817","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li C, Lu Y, Liu C, Yang W. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol. 2022;13:1016817. https:\/\/doi.org\/10.3389\/fimmu.2022.1016817.","journal-title":"Front Immunol"},{"issue":"11","key":"2075_CR15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337. https:\/\/doi.org\/10.1038\/nm.3394.","journal-title":"Nat Med"},{"issue":"4","key":"2075_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1164\/rccm.201409-1671PP","volume":"191","author":"R Remark","year":"2015","unstructured":"Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med. 2015;191(4):377\u201390. https:\/\/doi.org\/10.1164\/rccm.201409-1671PP.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2075_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2015.07.044","volume":"380","author":"Y Sun","year":"2016","unstructured":"Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016;380(1):205\u201315. https:\/\/doi.org\/10.1016\/j.canlet.2015.07.044.","journal-title":"Cancer Lett"},{"key":"2075_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6283796","volume":"2020","author":"R Wei","year":"2020","unstructured":"Wei R, Liu S, Zhang S, Min L, Zhu S. Cellular and extracellular components in tumor microenvironment and their application in early diagnosis of cancers. Anal Cell Pathol (Amst). 2020;2020:6283796. https:\/\/doi.org\/10.1155\/2020\/6283796.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"2075_CR19","unstructured":"Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Okumura H et al. Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res 2003 Sep-Oct;23(5A):4079\u201383."},{"issue":"7","key":"2075_CR20","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.18632\/oncotarget.6958","volume":"7","author":"HS Choi","year":"2016","unstructured":"Choi HS, Ha SY, Kim HM, Ahn SM, Kang MS, Kim KM, et al. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget. 2016;7(7):7940\u201351. https:\/\/doi.org\/10.18632\/oncotarget.6958.","journal-title":"Oncotarget"},{"issue":"10","key":"2075_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05320-8","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Wang X, Wang X, Xu M, Sheng W. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. Cell Death Dis. 2022;13(10):874. https:\/\/doi.org\/10.1038\/s41419-022-05320-8.","journal-title":"Cell Death Dis"},{"key":"2075_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.803974","volume":"11","author":"Y Yang","year":"2022","unstructured":"Yang Y, Meng WJ, Wang ZQ. Cancer stem cells and the tumor microenvironment in gastric cancer. Front Oncol. 2022;11:803974. https:\/\/doi.org\/10.3389\/fonc.2021.803974.","journal-title":"Front Oncol"},{"issue":"5","key":"2075_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","volume":"7","author":"DQ Zeng","year":"2019","unstructured":"Zeng DQ, Li MY, Zhou R, Zhang J, Sun H, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7(5):737\u201350. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0436.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2075_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06875-4","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Dong Y, Yu S, Hu k, Zhang L, et al. IL-4\/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fc\u03b3 receptor IIB in M2 macrophages. Cell Death Dis. 2024;15(7):500. https:\/\/doi.org\/10.1038\/s41419-024-06875-4.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2075_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/nu16020312","volume":"16","author":"L Wang","year":"2024","unstructured":"Wang L, Niu X. Immunoregulatory roles of osteopontin in diseases. Nutrients. 2024;16(2):312. https:\/\/doi.org\/10.3390\/nu16020312.","journal-title":"Nutrients"},{"issue":"12","key":"2075_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121558","volume":"8","author":"IA Mohamed","year":"2019","unstructured":"Mohamed IA, Gadeau AP, Hasan A, Abdulrahman N, Mraiche F. Osteopontin: a promising therapeutic target in cardiac fibrosis. Cells. 2019;8(12):1558. https:\/\/doi.org\/10.3390\/cells8121558.","journal-title":"Cells"},{"issue":"4","key":"2075_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0092-8674(79)90103-X","volume":"16","author":"DR Senger","year":"1979","unstructured":"Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16(4):885\u201393. https:\/\/doi.org\/10.1016\/0092-8674(79)90103-X.","journal-title":"Cell"},{"key":"2075_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.003","volume":"59","author":"MA Icer","year":"2018","unstructured":"Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17\u201324. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.07.003.","journal-title":"Clin Biochem"},{"issue":"1","key":"2075_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1084\/jem.170.1.145","volume":"170","author":"R Patarca","year":"1989","unstructured":"Patarca R, Freeman GJ, Singh RP, Wei FY, Durfee T, Blattner F, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med. 1989;170(1):145\u201361. https:\/\/doi.org\/10.1084\/jem.170.1.145.","journal-title":"J Exp Med"},{"issue":"2","key":"2075_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jss.2004.03.028","volume":"121","author":"PY Wai","year":"2004","unstructured":"Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res. 2004;121(2):228\u201341. https:\/\/doi.org\/10.1016\/j.jss.2004.03.028.","journal-title":"J Surg Res"},{"issue":"4","key":"2075_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.molmet.2014.03.004","volume":"3","author":"F Kahles","year":"2014","unstructured":"Kahles F, Findeisen HM, Bruemmer D. Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014;3(4):384\u201393. https:\/\/doi.org\/10.1016\/j.molmet.2014.03.004.","journal-title":"Mol Metab"},{"key":"2075_CR32","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.919159","volume":"26","author":"J Si","year":"2020","unstructured":"Si J, Wang C, Zhang D, Wang B, Zhou Y. Osteopontin in bone metabolism and bone diseases. Med Sci Monit. 2020;26:e919159. https:\/\/doi.org\/10.12659\/MSM.919159.","journal-title":"Med Sci Monit"},{"issue":"11","key":"2075_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113379","volume":"15","author":"HR Moorman","year":"2020","unstructured":"Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, et al. Osteopontin: a key regulator of tumor progression and immunomodulation. Cancers (Basel). 2020;15(11):3379. https:\/\/doi.org\/10.3390\/cancers12113379.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2075_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071527","volume":"12","author":"VK Panda","year":"2024","unstructured":"Panda VK, Mishra B, Nath AN, Butti R, Yadav AS, et al. Osteopontin: a key multifaceted regulator in tumor progression and immunomodulation. Biomedicines. 2024;12(7):1527. https:\/\/doi.org\/10.3390\/biomedicines12071527.","journal-title":"Biomedicines"},{"issue":"1","key":"2075_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26187-w","volume":"8","author":"V Farrokhi","year":"2018","unstructured":"Farrokhi V, Chabot JR, Neubert H, Yang Z. Assessing the feasibility of neutralizing osteopontin with various therapeutic antibody modalities. Sci Rep. 2018;(1):7781. https:\/\/doi.org\/10.1038\/s41598-018-26187-w.","journal-title":"Sci Rep"},{"key":"2075_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.953283","volume":"12","author":"Y Tan","year":"2022","unstructured":"Tan Y, Zhao L, Yang YG, Liu W. The role of osteopontin in tumor progression through tumor associated macrophages. Front Oncol. 2022;12:953283. https:\/\/doi.org\/10.3389\/fonc.2022.953283.","journal-title":"Front Oncol"},{"issue":"12","key":"2075_CR37","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/carcin\/bgg139","volume":"24","author":"C Gao","year":"2003","unstructured":"Gao C, Guo H, Downey L, Marroquin C, Wei J, Kuo PC. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis. 2003;24(12):1871\u20138. https:\/\/doi.org\/10.1093\/carcin\/bgg139.","journal-title":"Carcinogenesis"},{"issue":"6","key":"2075_CR38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.matbio.2005.05.005","volume":"24","author":"Y Yokosaki","year":"2005","unstructured":"Yokosaki Y, Tanaka K, Higashikawa F, Yamashita K, Eboshida A. Structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol. 2005;24(6):418\u201327. https:\/\/doi.org\/10.1016\/j.matbio.2005.05.005.","journal-title":"Matrix Biol"},{"issue":"2","key":"2075_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/excr.2000.4941","volume":"258","author":"ST Barry","year":"2000","unstructured":"Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res. 2000;258(2):342\u201351. https:\/\/doi.org\/10.1006\/excr.2000.4941.","journal-title":"Exp Cell Res"},{"issue":"3","key":"2075_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/10454411000110030101","volume":"11","author":"J Sodek","year":"2000","unstructured":"Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000;11(3):279\u2013303. https:\/\/doi.org\/10.1177\/10454411000110030101.","journal-title":"Crit Rev Oral Biol Med"},{"issue":"10","key":"2075_CR41","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/art.24814","volume":"60","author":"SA Sharif","year":"2009","unstructured":"Sharif SA, Du X, Myles T, Song JJ, Price E, et al. Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum. 2009;60(10):2902\u201312. https:\/\/doi.org\/10.1002\/art.24814.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2075_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-25","volume":"11","author":"MS Beausoleil","year":"2011","unstructured":"Beausoleil MS, SchuLze EB, Goodale D, Postenka CO, Allan AL. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer. 2011;11(1):25. https:\/\/doi.org\/10.1186\/1471-2407-11-25.","journal-title":"BMC Cancer"},{"issue":"1","key":"2075_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bbcan.2017.02.005","volume":"1868","author":"MA Briones-Orta","year":"2017","unstructured":"Briones-Orta MA, Avenda\u00f1o-V\u00e1zquez SE, Aparicio-Bautista DI, Coombes JD, Weber GF, et al. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys Acta Rev Cancer. 2017;1868(1):93\u2013A108. https:\/\/doi.org\/10.1016\/j.bbcan.2017.02.005.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"9","key":"2075_CR44","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3390\/ijms19092557","volume":"19","author":"GF Weber","year":"2018","unstructured":"Weber GF. The phylogeny of osteopontin-analysis of the protein sequence. Int J Mol Sci. 2018;19(9):2557. https:\/\/doi.org\/10.3390\/ijms19092557.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2075_CR45","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/jth.15663","volume":"20","author":"S Peraramelli","year":"2022","unstructured":"Peraramelli S, Zhou Q, Zhou Q, Wanko B, Zhao L, et al. Thrombin cleavage of osteopontin initiates osteopontin\u2019s tumor-promoting activity. J Thromb Haemost. 2022;20(5):1256\u201370. https:\/\/doi.org\/10.1111\/jth.15663.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2075_CR46","doi-asserted-by":"publisher","first-page":"ZE10","DOI":"10.7860\/JCDR\/2015\/12872.6111","volume":"9","author":"V Subraman","year":"2015","unstructured":"Subraman V, Thiyagarajan M, Malathi N, Rajan ST. OPN - revisited. J Clin Diagn Res. 2015;9(6):ZE10-3. https:\/\/doi.org\/10.7860\/JCDR\/2015\/12872.6111.","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"2075_CR47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1158\/1078-0432.CCR-12-2788","volume":"19","author":"G Rao","year":"2013","unstructured":"Rao G, Wang H, Li B, Huang L, Xue D, et al. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin\/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res. 2013;19(4):785\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2788.","journal-title":"Clin Cancer Res"},{"key":"2075_CR48","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.12659\/MSM.913185","volume":"25","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Wen G, Sun Y, Shen Y, Zeng Y, et al. .Osteopontin promotes colorectal cancer cell invasion and the stem cell-like properties through the PI3K-AKT-GSK\/3\u03b2-\u03b2\/catenin pathway. Med Sci Monit. 2019;25:3014\u201325. https:\/\/doi.org\/10.12659\/MSM.913185.","journal-title":"Med Sci Monit"},{"issue":"2","key":"2075_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087930","volume":"9","author":"Y Jin","year":"2014","unstructured":"Jin Y, Chen J, Feng Z, Zhang Z, Fan W, et al. OPN and \u03b1v\u03b23 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma. PLoS One. 2014;9(2):e87930. https:\/\/doi.org\/10.1371\/journal.pone.0087930.","journal-title":"PLoS One"},{"issue":"3","key":"2075_CR50","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/cas.13487","volume":"109","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Gao X, Yang J, Xu D, Zhang Y, et al. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci. 2018;109(3):710\u201323. https:\/\/doi.org\/10.1111\/cas.13487.","journal-title":"Cancer Sci"},{"issue":"1","key":"2075_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1186\/s12885-019-6014-5","volume":"19","author":"Y Feng","year":"2019","unstructured":"Feng Y, Su Y, Lin SL, 5, Lin P, Wu C, et al. Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer. BMC Cancer. 2019;19(1):791. https:\/\/doi.org\/10.1186\/s12885-019-6014-5.","journal-title":"BMC Cancer"},{"issue":"4","key":"2075_CR52","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1159\/000358670","volume":"33","author":"H Zhang","year":"2014","unstructured":"Zhang H, Guo M, Chen J, Wang Z, Du X, et al. Osteopontin knockdown inhibits \u03b1v,\u03b23 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K\/Akt\/mTOR pathway. Cell Physiol Biochem. 2014;33(4):991\u20131002. https:\/\/doi.org\/10.1159\/000358670.","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"2075_CR53","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/bjc.2014.664","volume":"112","author":"K Zduniak","year":"2015","unstructured":"Zduniak K, Ziolkowski P, Ahlin C, Agrawal A, Agrawal S, et al. Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer. 2015;112(4):729\u201338. https:\/\/doi.org\/10.1038\/bjc.2014.664.","journal-title":"Br J Cancer"},{"issue":"2","key":"2075_CR54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejso.2009.07.010","volume":"36","author":"MU Schuhmann","year":"2010","unstructured":"Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol. 2010;36(2):201\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2009.07.010.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"2075_CR55","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1158\/1055-9965.EPI-09-1077","volume":"19","author":"P Sreekanthreddy","year":"2010","unstructured":"Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1409\u201322. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-1077.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"2075_CR56","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.7150\/ijbs.21457","volume":"13","author":"JPC Wong","year":"2017","unstructured":"Wong JPC, Wei RLP, Tong OLH, Zhang. SDet al.Clinical and in vitro analysis of osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer. Int J Biol Sci. 2017;13(11):1373\u201386. https:\/\/doi.org\/10.7150\/ijbs.21457.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2075_CR57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.24703","volume":"55","author":"S Shang","year":"2012","unstructured":"Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483\u201390. https:\/\/doi.org\/10.1002\/hep.24703.","journal-title":"Hepatology"},{"issue":"12","key":"2075_CR58","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.7150\/jca.20480","volume":"8","author":"R Wei","year":"2017","unstructured":"Wei R, Wong JPC, Kwok HF. Osteopontin -- a promising biomarker for cancer therapy. J Cancer. 2017;8(12):2173\u201383. https:\/\/doi.org\/10.7150\/jca.20480.","journal-title":"J Cancer"},{"issue":"6","key":"2075_CR59","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/gut.2006.109868","volume":"56","author":"CY Wu","year":"2007","unstructured":"Wu CY, Wu MS, Chiang EP, Wu CH, et al. Elevated plasma osteopontin associated with gastric cancer development. Invasion Survival Gut. 2007;56(6):782\u20139. https:\/\/doi.org\/10.1136\/gut.2006.109868.","journal-title":"Invasion Survival Gut"},{"issue":"1\u20132","key":"2075_CR60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000111108","volume":"72","author":"N Dai","year":"2007","unstructured":"Dai N, Bao Q, Lu AP, Li JY, et al. Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology. 2007;72(1\u20132):89\u201396. https:\/\/doi.org\/10.1159\/000111108.","journal-title":"Oncology"},{"issue":"5","key":"2075_CR61","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/0008-5472.CAN-06-3625","volume":"67","author":"JL Lee","year":"2007","unstructured":"Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, et al. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007;67(5):2089\u201397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3625.","journal-title":"Cancer Res"},{"issue":"1","key":"2075_CR62","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/07357900701519279","volume":"26","author":"HW Tang","year":"2008","unstructured":"Tang HW, Wang J, Bai FH, Zhai HH, et al. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest. 2008;26(1):60\u20137. https:\/\/doi.org\/10.1080\/07357900701519279.","journal-title":"Cancer Invest"},{"issue":"9","key":"2075_CR63","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s11605-009-0955-y","volume":"13","author":"M Imano","year":"2009","unstructured":"Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, et al. Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg. 2009;13(9):1577\u201382. https:\/\/doi.org\/10.1007\/s11605-009-0955-y.","journal-title":"J Gastrointest Surg"},{"key":"2075_CR64","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3760\/cma.j.issn.1006-9801.2019.06.007","volume":"6","author":"WW Yu","year":"2019","unstructured":"Yu WW, Wang H, Zhang J, Kong Y, Qu FJ. Expressions of osteopontin, matrix metalloproteinase 2 and vascular endothelial growth factor in gastric cancer and their prognostic value. Cancer Res Clin. 2019;6:390\u20134. https:\/\/doi.org\/10.3760\/cma.j.issn.1006-9801.2019.06.007.","journal-title":"Cancer Res Clin"},{"issue":"2","key":"2075_CR65","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10120-015-0495-y","volume":"19","author":"MD Bartolomeo","year":"2016","unstructured":"Bartolomeo MD, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, et al. Osteopontin, E-cadherin, and \u03b2-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer. 2016;19(2):412\u201320. https:\/\/doi.org\/10.1007\/s10120-015-0495-y.","journal-title":"Gastric Cancer"},{"key":"2075_CR66","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2174\/1386207323666200902135349","volume":"24","author":"O Yazici","year":"2020","unstructured":"Yazici O, Dogan M, Ozal G, Aktas SH, Demirkazik A, Utkan G, Senler FC, Icli F, Akbulut H. Osteopontin is a prognostic factor in patients with advanced gastric cancer. Comb Chem High Throughput Screen. 2020;24:1229\u201335. https:\/\/doi.org\/10.2174\/1386207323666200902135349.","journal-title":"Comb Chem High Throughput Screen"},{"issue":"43","key":"2075_CR67","doi-asserted-by":"publisher","first-page":"69666","DOI":"10.18632\/oncotarget.11936","volume":"7","author":"X Gu","year":"2016","unstructured":"Gu X, Gao XS, Ma M, Qin S, Qi X, Li X, et al. Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis. Oncotarget. 2016;7(43):69666\u201373. https:\/\/doi.org\/10.18632\/oncotarget.11936.","journal-title":"Oncotarget"},{"issue":"7","key":"2075_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071820","volume":"10","author":"C Hao","year":"2021","unstructured":"Hao C, Cui Y, Lane J, Jia S, Ji J, Jiang WG. Distinctive prognostic value and cellular functions of osteopontin splice variants in human gastric cancer. Cells. 2021;10(7):1820. https:\/\/doi.org\/10.3390\/cells10071820.","journal-title":"Cells"},{"issue":"16","key":"2075_CR69","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1038\/onc.2013.171","volume":"33","author":"R Raja","year":"2014","unstructured":"Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, et al. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1\u03b1-mediated VEGF-dependent angiogenesis. Oncogene. 2014;33(16):2053\u201364. https:\/\/doi.org\/10.1038\/onc.2013.171.","journal-title":"Oncogene"},{"issue":"9","key":"2075_CR70","first-page":"1873","volume":"6","author":"CQ Wang","year":"2016","unstructured":"Wang CQ, Sun HT, Gao XM, Ren N, Sheng YY, et al. Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. Am J Cancer Res. 2016;6(9):1873\u201389. eCollection 2016.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2075_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0391-6","volume":"9","author":"H Zhao","year":"2018","unstructured":"Zhao H, Chen Q, Alam A, Cui J, Suen KC, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9(3):356. https:\/\/doi.org\/10.1038\/s41419-018-0391-6.","journal-title":"Cell Death Dis"},{"issue":"9","key":"2075_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/biom11091323","volume":"11","author":"Y Kariya","year":"2021","unstructured":"Kariya Y, Oyama M, Kariya Y, Hashimoto Y. Phosphorylated osteopontin secreted from cancer cells induces cancer cell motility. Biomol. 2021;11(9):1323. https:\/\/doi.org\/10.3390\/biom11091323.","journal-title":"Biomol"},{"issue":"1","key":"2075_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/neuonc\/nop013","volume":"12","author":"HJ Jan","year":"2010","unstructured":"Jan HJ, Lee CH, Shih YL, Hueng DY, Ma HI, et al. Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neurooncology. 2010;12(1):58\u201370. https:\/\/doi.org\/10.1093\/neuonc\/nop013.","journal-title":"Neurooncology"},{"issue":"8","key":"2075_CR74","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/neuonc\/noq006","volume":"12","author":"W Yan","year":"2010","unstructured":"Yan W, Qian C, Zhao P, Zhang J, Shi L, et al. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol. 2010;12(8):765\u201375. https:\/\/doi.org\/10.1093\/neuonc\/noq006.","journal-title":"Neuro Oncol"},{"issue":"11","key":"2075_CR75","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/neuonc\/nos262","volume":"14","author":"DY Lu","year":"2012","unstructured":"Lu DY, Yeh WL, Huang SM, Tang CH, Lin HY, et al. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro Oncol. 2012;14(11):1367\u201378. https:\/\/doi.org\/10.1093\/neuonc\/nos262.","journal-title":"Neuro Oncol"},{"issue":"8","key":"2075_CR76","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/ijc.24751","volume":"126","author":"V Lamour","year":"2010","unstructured":"Lamour V, Mercier ML, Lefranc F, Hagedorn M, Javerzat S, et al. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer. 2010;126(8):1797\u2013805. https:\/\/doi.org\/10.1002\/ijc.24751.","journal-title":"Int J Cancer"},{"issue":"15","key":"2075_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153793","volume":"13","author":"K Amilca-Seba","year":"2021","unstructured":"Amilca-Seba K, Sabbah M, Larsen AK, Denis JA. Osteopontin as a regulator of colorectal cancer progression and its clinical applications. Cancers (Basel). 2021;13(15):3793. https:\/\/doi.org\/10.3390\/cancers13153793.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2075_CR78","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1517\/14728222.2014.925447","volume":"18","author":"M Bandopadhyay","year":"2014","unstructured":"Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets. 2014;18(8):883\u201395. https:\/\/doi.org\/10.1517\/14728222.2014.925447.","journal-title":"Expert Opin Ther Targets"},{"key":"2075_CR79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.matbio.2014.03.001","volume":"37","author":"LA Shevde","year":"2014","unstructured":"Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014;37:131\u201341. https:\/\/doi.org\/10.1016\/j.matbio.2014.03.001.","journal-title":"Matrix Biol"},{"key":"2075_CR80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcdb.2016.08.032","volume":"64","author":"L Shi","year":"2017","unstructured":"Shi L, Wang X. Role of osteopontin in lung cancer evolution and heterogeneity. Semin Cell Dev Biol. 2017;64:40\u20137. https:\/\/doi.org\/10.1016\/j.semcdb.2016.08.032.","journal-title":"Semin Cell Dev Biol"},{"issue":"8B","key":"2075_CR81","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/j.1582-4934.2008","volume":"13","author":"G Song","year":"2009","unstructured":"Song G, Ouyang GL, Mao YB, Ming YL, et al. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med. 2009;13(8B):1706\u201318. https:\/\/doi.org\/10.1111\/j.1582-4934.2008. 00540. X.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2075_CR82","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3892\/or.2011.1168","volume":"25","author":"ZM Wang","year":"2011","unstructured":"Wang ZM, Cui YH, Li W, Chen SY, Liu TS. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells. Oncol Rep. 2011;25(4):997\u20131003. https:\/\/doi.org\/10.3892\/or.2011.1168.","journal-title":"Oncol Rep"},{"issue":"6","key":"2075_CR83","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/labinvest.2015.47","volume":"95","author":"JW Park","year":"2015","unstructured":"Park JW, Lee SH, Go DM, Kim HK, et al. Osteopontin depletion decreases inflammation and gastric epithelial proliferation during Helicobacter pylori infection in mice. Lab Invest. 2015;95(6):660\u201371. https:\/\/doi.org\/10.1038\/labinvest.2015.47.","journal-title":"Lab Invest"},{"issue":"9","key":"2075_CR84","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.4251\/wjgo.v15.i9.1544","volume":"15","author":"YC Qin","year":"2023","unstructured":"Qin YC, Yan X, Yuan XL, Yu WW, Qu FJ. Osteopontin promotes gastric cancer progression via phosphatidylinositol-3-kinase\/protein kinase B\/mammalian target of rapamycin signaling pathway. World J Gastrointest Oncol. 2023;15(9):1544\u201355. https:\/\/doi.org\/10.4251\/wjgo.v15.i9.1544.","journal-title":"World J Gastrointest Oncol"},{"issue":"10","key":"2075_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21055","volume":"9","author":"Z Yan","year":"2023","unstructured":"Yan Z, Hu X, Tang B, Deng F. Role of osteopontin in cancer development and treatment. Heliyon. 2023;9(10):e21055. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21055.","journal-title":"Heliyon"},{"issue":"5","key":"2075_CR86","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/ijc.10261","volume":"98","author":"F Takahashi","year":"2002","unstructured":"Takahashi F, Akutagawa S, Fukumoto H, Tsukiyama S, Ohe Y, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer. 2002;98(5):707\u201312. https:\/\/doi.org\/10.1002\/ijc.10261.","journal-title":"Int J Cancer"},{"issue":"1","key":"2075_CR87","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1158\/0008-5472.CAN-07-2126","volume":"68","author":"G Chakraborty","year":"2008","unstructured":"Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68(1):152\u201361. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2126.","journal-title":"Cancer Res"},{"issue":"42","key":"2075_CR88","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/onc.2015.315","volume":"34","author":"S Kale","year":"2015","unstructured":"Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via \u03b19\u03b21 integrin. Oncogene. 2015;34(42):5408\u201310. https:\/\/doi.org\/10.1038\/onc.2015.315.","journal-title":"Oncogene"},{"issue":"2","key":"2075_CR89","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbrc.2007.05.104","volume":"359","author":"T Ogata","year":"2007","unstructured":"Ogata T, Ueyama T, Nomura T, Asada S, Tagawa M, et al. Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3- kinase\/Akt pathway. Biochem Biophys Res Commun. 2007;359(2):341\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.104.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2075_CR90","doi-asserted-by":"publisher","first-page":"615","DOI":"10.22034\/APJCP.2018.19.3.615","volume":"19","author":"A Mirzaei","year":"2018","unstructured":"Mirzaei A, Mohammadi S, Ghaffari SH, Yaghmaie M, Vaezi M, et al. Osteopontin b and c splice isoforms in leukemias and solid tumors: angiogenesis alongside chemoresistance. Asian Pac J Cancer Prev. 2018;19(3):615\u201323. https:\/\/doi.org\/10.22034\/APJCP.2018.19.3.615.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"2075_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051440","volume":"13","author":"K Osuka","year":"2023","unstructured":"Osuka K, Ohmichi Y, Ohmichi M, Honma S, Suzuki C, et al. Angiogenesis in the outer membrane of chronic subdural hematomas through thrombin-cleaved osteopontin and the integrin \u03b19 and integrin \u03b21 signaling pathways. Biomedicines. 2023;13(5):1440. https:\/\/doi.org\/10.3390\/biomedicines11051440.","journal-title":"Biomedicines"},{"issue":"3","key":"2075_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05658-w","volume":"150","author":"M Guo","year":"2024","unstructured":"Guo M, Liu M, Li W, Wang C, Zhang L, et al. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k\/Akt\/mTOR pathway. J Cancer Res Clin Oncol. 2024;150(3):155. https:\/\/doi.org\/10.1007\/s00432-024-05658-w.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2075_CR93","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10067-013-2375-3","volume":"33","author":"HI Ji","year":"2014","unstructured":"Ji HI, Lee SH, Song R, Yang HI, Lee YA, et al. Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis. Clin Rheumatol. 2014;33(3):397\u2013402. https:\/\/doi.org\/10.1007\/s10067-013-2375-3.","journal-title":"Clin Rheumatol"},{"key":"2075_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.023","author":"Y Morimoto","year":"2018","unstructured":"Morimoto Y, Hirahara K, Kiuchi M, Wada T, Ichikawa T, Kanno T, et al. Amphiregulin-producing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis. Immunity. 2018(1). https:\/\/doi.org\/10.1016\/j.immuni.2018.04.023.","journal-title":"Immunity"},{"issue":"9","key":"2075_CR95","doi-asserted-by":"publisher","first-page":"E856","DOI":"10.1073\/pnas.1316447111","volume":"111","author":"E Kourepini","year":"2014","unstructured":"Kourepini E, Aggelakopoulou M, Alissafi T, Paschalidis N, Simoes DC, Panoutsakopoulou V. Osteopontin expression by CD103- dendritic cells drives intestinal inflammation. Proc Natl Acad Sci U S A. 2014;111(9):E856\u201365. https:\/\/doi.org\/10.1073\/pnas.1316447111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2075_CR96","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cytogfr.2019.05.004","volume":"50","author":"AD Prete","year":"2019","unstructured":"Prete AD, Scutera S, Sozzani S, Musso T. Role of osteopontin in dendritic cell shaping of immune responses. Cytokine Growth Factor Rev. 2019;50:19\u201328. https:\/\/doi.org\/10.1016\/j.cytogfr.2019.05.004.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"2075_CR97","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/1756-185X.12115","volume":"17","author":"H Iwadate","year":"2014","unstructured":"Iwadate H, Kobayashi H, Kanno T, Asano T, Saito T. Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. Int J Rheum Dis. 2014;17(1):50\u20136. https:\/\/doi.org\/10.1111\/1756-185X.12115.","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"2075_CR98","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1440-1827.2011.02649.x","volume":"61","author":"T Uede","year":"2011","unstructured":"Uede T. Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int. 2011;61(5):265\u201380. https:\/\/doi.org\/10.1111\/j.1440-1827.2011.02649.x.","journal-title":"Pathol Int"},{"issue":"2","key":"2075_CR99","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10787-022-00932-0","volume":"30","author":"C Xu","year":"2022","unstructured":"Xu C, Wu Y, Liu N. Osteopontin in autoimmune disorders: current knowledge and future perspective. Inflammopharmacology. 2022;30(2):385\u201396. https:\/\/doi.org\/10.1007\/s10787-022-00932-0.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"2075_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0832-1","volume":"37","author":"X Gao","year":"2018","unstructured":"Gao X, Sheng Y, Yang J, Wang C, Zhang R, et al. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+\/CD44\u2009+\u2009cancer stem cells to 5 azacytidine in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):179. https:\/\/doi.org\/10.1186\/s13046-018-0832-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2075_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02852-5","volume":"42","author":"X Gao","year":"2023","unstructured":"Gao X, Sheng Y, Yang J, Wang C, Zhang R, et al. Correction: osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+\/CD44\u2009+\u2009cancer stem cells to 5 azacytidine in hepatocellular carcinoma. J Exp Clin Cancer Res. 2023;42(1):266. https:\/\/doi.org\/10.1186\/s13046-023-02852-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2075_CR102","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.4049\/jimmunol.1701345","volume":"200","author":"T Alissafi","year":"2018","unstructured":"Alissafi T, Kourepini E, Simoes DCM, Paschalidis N, Aggelakopoulou M, et al. Osteopontin promotes protective antigenic tolerance against experimental allergic airway disease. J Immunol. 2018;200(4):1270\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1701345.","journal-title":"J Immunol"},{"issue":"2","key":"2075_CR103","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/1756-185X.14021","volume":"24","author":"A Hejrati","year":"2021","unstructured":"Hejrati A, Hasani B, Esmaili M, Bashash D, Tavakolinia N, Zafari P. Role of exosome in autoimmunity, with a particular emphasis on rheumatoid arthritis. Int J Rheum Dis. 2021;24(2):159\u201369. https:\/\/doi.org\/10.1111\/1756-185X.14021.","journal-title":"Int J Rheum Dis"},{"issue":"23","key":"2075_CR104","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"LB McInnes","year":"2011","unstructured":"McInnes LB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205\u201319. https:\/\/doi.org\/10.1056\/NEJMra1004965.","journal-title":"N Engl J Med"},{"key":"2075_CR105","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.intimp.2017.12.028","volume":"55","author":"BB Mehta","year":"2018","unstructured":"Mehta BB, Sharma S, Vasishta RK, Sen RK, Sharma A, et al. Blocking osteopontin-fibronectin interactions reduce extracellular fibronectin deployment and arthritic immunopathology. Int Immunopharmacol. 2018;55:297\u2013305. https:\/\/doi.org\/10.1016\/j.intimp.2017.12.028.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2075_CR106","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.gendis.2022.08.010","volume":"10","author":"W Luo","year":"2022","unstructured":"Luo W, Lin Z, Yuan Y, Wu Z, Zhong W, Liu Q. Osteopontin (OPN) alleviates the progression of osteoarthritis by promoting the anabolism of chondrocytes. Genes Dis. 2022;10(4):1714\u201325. https:\/\/doi.org\/10.1016\/j.gendis.2022.08.010.","journal-title":"Genes Dis"},{"issue":"8","key":"2075_CR107","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1111\/cas.14521","volume":"111","author":"Y Oya","year":"2020","unstructured":"Oya Y, Hayakawa Y, Koike K. Tumor microenvironment in gastric cancers. Cancer Sci. 2020;111(8):2696\u2013707. https:\/\/doi.org\/10.1111\/cas.14521.","journal-title":"Cancer Sci"},{"issue":"6","key":"2075_CR108","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrd.2016.111","volume":"15","author":"C Morrison","year":"2016","unstructured":"Morrison C. Immuno-oncologists eye up macrophage targets. Nat Rev Drug Discov. 2016;15(6):373\u20134. https:\/\/doi.org\/10.1038\/nrd.2016.111.","journal-title":"Nat Rev Drug Discov"},{"key":"2075_CR109","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molimm.2017.12.003","volume":"110","author":"KB Long","year":"2019","unstructured":"Long KB, Collier AI, Beatty GL. Macrophages: key orchestrators of a tumor microenvironment defined by therapeutic resistance. Mol Immunol. 2019;110:3\u201312. https:\/\/doi.org\/10.1016\/j.molimm.2017.12.003.","journal-title":"Mol Immunol"},{"key":"2075_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01731","volume":"4","author":"K Wu","year":"2020","unstructured":"Wu K, Lin K, Li X, Yuan X, Xu P, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;4:1731. https:\/\/doi.org\/10.3389\/fimmu.2020.01731.","journal-title":"Front Immunol"},{"key":"2075_CR111","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5669635","volume":"5","author":"Y Li","year":"2021","unstructured":"Li Y, Li JQ, Jiang HP, Li X. The upregulation of PLXDC2 correlates with immune microenvironment characteristics and predicts prognosis in gastric cancer. Dis Markers. 2021;5:5669635. https:\/\/doi.org\/10.1155\/2021\/5669635.","journal-title":"Dis Markers"},{"issue":"1","key":"2075_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11911-5","volume":"10","author":"F Zhang","year":"2019","unstructured":"Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10(1):3974. https:\/\/doi.org\/10.1038\/s41467-019-11911-5.","journal-title":"Nat Commun"},{"issue":"5","key":"2075_CR113","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s13402-019-00453-z","volume":"42","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A, Valilou SF, Soltani A, Ahmadi S, Abarghan YJ, et al. Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol (Dordr). 2019;42(5):591\u2013608. https:\/\/doi.org\/10.1007\/s13402-019-00453-z.","journal-title":"Cell Oncol (Dordr)"},{"key":"2075_CR114","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9720912","volume":"2016","author":"Q Guo","year":"2016","unstructured":"Guo Q, Jin Z, Yuan Y, Liu R, Xu T, Wei H, et al. New mechanisms of tumorassociated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy. J Immunol. 2016;2016:9720912. https:\/\/doi.org\/10.1155\/2016\/9720912.","journal-title":"J Immunol"},{"key":"2075_CR115","doi-asserted-by":"publisher","unstructured":"Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T et al. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of TumorPromoting Macrophages via Repression of CD8(+) T Cell-Derived Interferon-Gamma. Immunity.2019;51(2):381\u2013397.e6. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.017","DOI":"10.1016\/j.immuni.2019.06.017"},{"issue":"1","key":"2075_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105(1):1\u20138. https:\/\/doi.org\/10.1111\/cas.12314.","journal-title":"Cancer Sci"},{"issue":"Pt B","key":"2075_CR117","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","volume":"99","author":"Y Komohara","year":"2016","unstructured":"Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2016;99(Pt B):180\u20135. https:\/\/doi.org\/10.1016\/j.addr.2015.11.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"2075_CR118","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1158\/1078-0432.ccr-03-0300","volume":"10","author":"N Yamanaka","year":"2004","unstructured":"Yamanaka N, Morisaki T, Nakashima H, Tasaki A, Kubo M, et al. Interleukin 1beta enhances invasive ability of gastric carcinoma through nuclear factor-kappaB activation. Clin Cancer Res. 2004;10(5):1853\u20139. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0300.","journal-title":"Clin Cancer Res"},{"key":"2075_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102015","volume":"86","author":"V Gambardella","year":"2020","unstructured":"Gambardella V, Castillo J, Tarazona N, Gimeno-Valiente F, Mart\u00ednez-Ciarpaglini C, et al. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev. 2020;86:102015. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102015.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"2075_CR120","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1136\/gutjnl-2016-312779","volume":"67","author":"CP Petersen","year":"2018","unstructured":"Petersen CP, Meyer AR, De Salvo C, Choi E, Schlegel C, et al. A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut. 2018;67(5):805\u201317. https:\/\/doi.org\/10.1136\/gutjnl-2016-312779.","journal-title":"Gut"},{"issue":"7","key":"2075_CR121","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/sj.emboj.7600170","volume":"23","author":"H Oshima","year":"2004","unstructured":"Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2\/mPGES\u20101 transgenic mice. EMBO J. 2004;23(7):1669\u201378. https:\/\/doi.org\/10.1038\/sj.emboj.7600170.","journal-title":"EMBO J"},{"key":"2075_CR122","doi-asserted-by":"publisher","unstructured":"Kaparakis M, Walduck AK, Price JD, van Pedersen N et al. Macrophages are mediators of gastritis in acute Helicobacter pylori infection in C57BL\/6 mice. Infect Immun. 2008;76(5):2235-9. https:\/\/doi.org\/10.1128\/IAI.01481-07","DOI":"10.1128\/IAI.01481-07"},{"issue":"12","key":"2075_CR123","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/emboj.2008.105","volume":"27","author":"K Oguma","year":"2008","unstructured":"Oguma K, Oshima H, Aoki M, Uchio R, Naka K, et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008;27(12):1671\u201381. https:\/\/doi.org\/10.1038\/emboj.2008.105.","journal-title":"EMBO J"},{"issue":"2","key":"2075_CR124","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1053\/j.gastro.2010.11.007","volume":"140","author":"H Oshima","year":"2011","unstructured":"Oshima H, Hioki K, Popivanova BK, Oguma K, Rooijen NV, et al. Prostaglandin E(2) signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology. 2011;140(2):596-607.e7. https:\/\/doi.org\/10.1053\/j.gastro.2010.11.007.","journal-title":"Gastroenterology"},{"issue":"21","key":"2075_CR125","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.1158\/0008-5472.CAN-10-1506","volume":"70","author":"T Okumura","year":"2010","unstructured":"Okumura T, Ericksen RE, Takaishi S, Wang SSW, Dubeykovskiy Z, et al. K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia. Cancer Res. 2010;70(21):8435\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1506.","journal-title":"Cancer Res"},{"issue":"7","key":"2075_CR126","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1053\/j.gastro.2014.02.007","volume":"146","author":"CP Petersen","year":"2014","unstructured":"Petersen CP, Weis VG, Nam KT, Sousa JF, Fingleton B, Goldenring JR. Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells. Gastroenterology. 2014;146(7):1727-38.e8. https:\/\/doi.org\/10.1053\/j.gastro.2014.02.007.","journal-title":"Gastroenterology"},{"issue":"1","key":"2075_CR127","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/path.5163","volume":"247","author":"H Kinoshita","year":"2019","unstructured":"Kinoshita H, Hayakawa Y, Konishi M, Hata M, Tsuboi M, et al. Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium. J Pathol. 2019;247(1):35\u201347. https:\/\/doi.org\/10.1002\/path.5163.","journal-title":"J Pathol"},{"issue":"1","key":"2075_CR128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2567.2010.03335.x","volume":"132","author":"NA Atai","year":"2011","unstructured":"Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011;132(1):39\u201348. https:\/\/doi.org\/10.1111\/j.1365-2567.2010.03335.x.","journal-title":"Immunology"},{"issue":"3","key":"2075_CR129","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3978\/j.issn.2304-3881.2014.02.09","volume":"3","author":"KH Liang","year":"2014","unstructured":"Liang KH, Yeh CT. OPN sesame. Hepatobiliary Surg Nutr. 2014;3(3):112\u20134. https:\/\/doi.org\/10.3978\/j.issn.2304-3881.2014.02.09.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"9","key":"2075_CR130","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, et al. Disruption of Tumour-Associated macrophage trafficking by the Osteopontin-Induced Colony-Stimulating Factor-1 signalling sensitises hepatocellular carcinoma to Anti-PD-L1 Blockade. Gut. 2019;68(9):1653\u201366. https:\/\/doi.org\/10.1136\/gutjnl-2019-318419.","journal-title":"Gut"},{"issue":"10","key":"2075_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/genes13101760","volume":"13","author":"K Chen","year":"2022","unstructured":"Chen K, Wang Q, Liu X, Wang F, Ma Y, et al. Single cell RNA-Seq identifies immune-related prognostic model and key signature-SPP1 in pancreatic ductal adenocarcinoma. Genes. 2022;13(10):1760. https:\/\/doi.org\/10.3390\/genes13101760.","journal-title":"Genes"},{"issue":"1","key":"2075_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1114-3","volume":"15","author":"CN Lin","year":"2015","unstructured":"Lin CN, Wang CJ, Chao YJ, Lai MD, Shan YS. The significance of the coexistence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer. 2015;15(1):128. https:\/\/doi.org\/10.1186\/s12885-015-1114-3.","journal-title":"BMC Cancer"},{"issue":"1","key":"2075_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010164","volume":"15","author":"W Xie","year":"2022","unstructured":"Xie W, Cheng J, Hong Z, Cai W, Zhuo H, et al. Multi-transcriptomic analysis reveals the heterogeneity and tumor-promoting role of SPP1\/CD44\u2013mediated intratumoral crosstalk in gastric cancer. Cancers (Basel). 2022;15(1):164. https:\/\/doi.org\/10.3390\/cancers15010164.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"2075_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133253","volume":"13","author":"I Larionova","year":"2021","unstructured":"Larionova I, Kazakova E, Gerashchenko T, Kzhyshkowska J. New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis. Cancers (Basel). 2021;13(13):3253. https:\/\/doi.org\/10.3390\/cancers13133253.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2075_CR135","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","volume":"181","author":"S Kusmartsev","year":"2008","unstructured":"Kusmartsev S, Eruslanov E, K\u00fcbler H, Tseng T, Sakai Y, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181(1):346\u201353. https:\/\/doi.org\/10.4049\/jimmunol.181.1.346.","journal-title":"J Immunol"},{"issue":"1","key":"2075_CR136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12307-014-0160-8","volume":"8","author":"YY Elamin","year":"2015","unstructured":"Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron. 2015;8(1):15\u201321. https:\/\/doi.org\/10.1007\/s12307-014-0160-8.","journal-title":"Cancer Microenviron"},{"issue":"7","key":"2075_CR137","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632\u201342. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0053.","journal-title":"Cancer Immunol Res"},{"key":"2075_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. https:\/\/doi.org\/10.1038\/ncomms12624.","journal-title":"Nat Commun"},{"issue":"536","key":"2075_CR139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay8456","volume":"12","author":"CJ Martin","year":"2020","unstructured":"Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, et al. Selective inhibition of TGF\u03b21 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Transl Med. 2020;12(536):eaay8456. https:\/\/doi.org\/10.1126\/scitranslmed.aay8456.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2075_CR140","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/jso.23110","volume":"106","author":"H Wu","year":"2012","unstructured":"Wu H, Xu JB, He YL, Peng JJ, Zhang XH, et al. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J Surg Oncol. 2012;106(4):462\u20138. https:\/\/doi.org\/10.1002\/jso.23110.","journal-title":"J Surg Oncol"},{"issue":"11","key":"2075_CR141","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JM Chan","year":"2021","unstructured":"Chan JM, Quintanal-Villalonga A, Gao VR, Xie Y, Allaj V, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39(11):1479-1496.e18. https:\/\/doi.org\/10.1016\/j.ccell.2021.09.008.","journal-title":"Cancer Cell"},{"issue":"8","key":"2075_CR142","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.4049\/jimmunol.2100202","volume":"207","author":"A Hansakon","year":"2021","unstructured":"Hansakon A, Png CW, Zhang Y, Angkasekwinai P. Macrophage-derived osteopontin influences the amplification of Cryptococcus neoformans-promoting type 2 immune response. J Immunol. 2021;207(8):2107\u201317. https:\/\/doi.org\/10.4049\/jimmunol.2100202.","journal-title":"J Immunol"},{"issue":"27","key":"2075_CR143","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959\u201366. https:\/\/doi.org\/10.1200\/JCO.2013.55.0491.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2075_CR144","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1291106","volume":"6","author":"C Lu","year":"2017","unstructured":"Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology. 2017;6(3):e1291106. https:\/\/doi.org\/10.1080\/2162402X.2017.1291106.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2075_CR145","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw283","volume":"109","author":"C Lu","year":"2017","unstructured":"Lu C, Paschall AV, Shi H, Savage N, Waller JL, et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017;109(6):djw283. https:\/\/doi.org\/10.1093\/jnci\/djw283.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2075_CR146","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.hbpd.2018.03.007","volume":"17","author":"HL Gao","year":"2018","unstructured":"Gao HL, Liu L, Qi ZH, Xu HX, Wang WQ, et al. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: a metaanalysis. Hepatobiliary Pancreat Dis Int. 2018;17(2):95\u2013100. https:\/\/doi.org\/10.1016\/j.hbpd.2018.03.007.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"2","key":"2075_CR147","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001100","volume":"8","author":"MB Ware","year":"2020","unstructured":"Ware MB, El-Rayes BF, Lesinski GB. Mirage or long-awaited OASIS: reinvigorating T-cell responses in pancreatic cancer. J Immunother Cancer. 2020;8(2):e001100. https:\/\/doi.org\/10.1136\/jitc-2020-001100.","journal-title":"J Immunother Cancer"},{"issue":"59","key":"2075_CR148","doi-asserted-by":"publisher","first-page":"99372","DOI":"10.18632\/oncotarget.22079","volume":"8","author":"X Ju","year":"2017","unstructured":"Ju X, Shen R, Huang P, ZhaiJ, Qian X, et al. Predictive relevance of PD-L1 expression with pre-existing TILs. Gastric Cancer Oncotarget. 2017;8(59):99372\u201381. https:\/\/doi.org\/10.18632\/oncotarget.22079. eCollection 2017 Nov 21.","journal-title":"Gastric Cancer Oncotarget"},{"issue":"12","key":"2075_CR149","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1172\/JCI123360","volume":"128","author":"JD Klement","year":"2018","unstructured":"Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, et al. An osteopontin\/CD44 immune checkpoint controls CD8\u2009+\u2009T cell activation and tumor immune evasion. J Clin Invest. 2018;128(12):5549\u201360. https:\/\/doi.org\/10.1172\/JCI123360.","journal-title":"J Clin Invest"},{"issue":"12","key":"2075_CR150","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1172\/JCI124918","volume":"128","author":"MR Shurin","year":"2018","unstructured":"Shurin MR. Osteopontin controls immunosuppression in the tumor microenvironment. J Clin Invest. 2018;128(12):5209\u201312. https:\/\/doi.org\/10.1172\/JCI124918.","journal-title":"J Clin Invest"},{"issue":"3","key":"2075_CR151","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.immuni.2016.08.013","volume":"45","author":"D Sichien","year":"2016","unstructured":"Sichien D, Scott CL, Martens L, Vanderkerken M, Gassen SV, et al. IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells. Respectively Immun. 2016;45(3):626\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2016.08.013.","journal-title":"Respectively Immun"},{"issue":"5","key":"2075_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051006","volume":"13","author":"JD Klement","year":"2021","unstructured":"Klement JD, Poschel DB, Lu C, Merting AD, Yang D, et al. Osteopontin blockade immunotherapy increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor progression. Cancers (Basel). 2021;13(5):1006. https:\/\/doi.org\/10.3390\/cancers13051006.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2075_CR153","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1634\/stemcells.2008-0370","volume":"26","author":"JW Chung","year":"2008","unstructured":"Chung JW, Kim MS, Piao ZH, Jeong M, Yoon SR, et al. Osteopontin promotes the development of natural killer cells from hematopoietic stem cells. Stem Cells. 2008;26(8):2114\u201323. https:\/\/doi.org\/10.1634\/stemcells.2008-0370.","journal-title":"Stem Cells"},{"issue":"2","key":"2075_CR154","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1073\/pnas.1423011112","volume":"112","author":"JW Leavenworth","year":"2015","unstructured":"Leavenworth JW, Verbinnen B, Wang Q, Shen E, Cantor H. Intracellular osteopontin regulates homeostasis and function of natural killer cells. Proc Natl Acad Sci USA. 2015;112(2):494\u20139. https:\/\/doi.org\/10.1073\/pnas.1423011112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2075_CR155","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/690571","volume":"2012","author":"A Amedei","year":"2012","unstructured":"Amedei A, Bella CD, Silvestri E, Prisco D, D\u2019Elios MM. T cells in gastric cancer: friends or foes. Clin Dev Immunol. 2012;2012:690571. https:\/\/doi.org\/10.1155\/2012\/690571.","journal-title":"Clin Dev Immunol"},{"issue":"17","key":"2075_CR156","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1158\/0008-5472.CAN-13-3334","volume":"74","author":"S Sangaletti","year":"2014","unstructured":"Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 2014;74(17):4706\u201319. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3334.","journal-title":"Cancer Res"},{"issue":"22","key":"2075_CR157","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1158\/0008-5472.CAN-14-1482","volume":"74","author":"E Kim","year":"2014","unstructured":"Kim E, Jeon I, Seo H, Park YJ, Song B, et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res. 2014;74(22):6705\u201316. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1482.","journal-title":"Cancer Res"},{"issue":"20","key":"2075_CR158","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers13205246","volume":"13","author":"P De","year":"2021","unstructured":"De P, Aske J, Dey N. Cancer-associated fibroblast functions as a road-block in cancer therapy. Cancers (Basel). 2021;13(20):19. https:\/\/doi.org\/10.3390\/cancers13205246.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2075_CR159","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/14737140.2022.2019018","volume":"22","author":"J Suzuki","year":"2022","unstructured":"Suzuki J, Tsuboi M, Ishii G. Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer. Expert Rev Anticancer Ther. 2022;22(2):169\u201382. https:\/\/doi.org\/10.1080\/14737140.2022.2019018.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"2075_CR160","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/path.4824","volume":"241","author":"Y Komohara","year":"2017","unstructured":"Komohara Y, Takeya M. CAFs and TAMs: maestros of the tumour microenvironment. J Pathol. 2017;241(3):313\u20135. https:\/\/doi.org\/10.1002\/path.4824.","journal-title":"J Pathol"},{"issue":"2","key":"2075_CR161","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/path.4769","volume":"240","author":"O Hashimoto","year":"2016","unstructured":"Hashimoto O, OYoshida M, Koma YI, Yanai T, Hasegawa D, et al. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development. J Pathol. 2016;240(2):211\u201323. https:\/\/doi.org\/10.1002\/path.4769. Epub 2016 Sep 19.","journal-title":"J Pathol"},{"issue":"5","key":"2075_CR162","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","volume":"16","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, et al. Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2019;16(5):282\u201395. https:\/\/doi.org\/10.1038\/s41575-019-0115-0.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2075_CR163","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante M, Tu SP, Tomita H, Gonda T, Wang SSW, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257\u201372. https:\/\/doi.org\/10.1016\/j.ccr.2011.01.020.","journal-title":"Cancer Cell"},{"issue":"4","key":"2075_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060914","volume":"8","author":"H Kinoshita","year":"2013","unstructured":"Kinoshita H, Hirata Y, Nakagawa H, Sakamoto K, Hayakawa Y, et al. Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. PLoS One. 2013;8(4):e60914. https:\/\/doi.org\/10.1371\/journal.pone.0060914.","journal-title":"PLoS One"},{"issue":"8","key":"2075_CR165","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/ijc.28520","volume":"134","author":"T Hasegawa","year":"2014","unstructured":"Hasegawa T, Yashiro M, Nishii T, Matsuoka J, Fuyuhiro Y, et al. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-\u03b2 signaling. Int J Cancer. 2014;134(8):1785\u201395. https:\/\/doi.org\/10.1002\/ijc.28520.","journal-title":"Int J Cancer"},{"issue":"4","key":"2075_CR166","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s10120-015-0579-8","volume":"19","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer. 2016;19(4):1052\u201365. https:\/\/doi.org\/10.1007\/s10120-015-0579-8.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2075_CR167","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1053\/j.gastro.2017.03.046","volume":"153","author":"T Ishimoto","year":"2017","unstructured":"Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology. 2017;153(1):191-204.e16. https:\/\/doi.org\/10.1053\/j.gastro.2017.03.046.","journal-title":"Gastroenterology"},{"issue":"4","key":"2075_CR168","doi-asserted-by":"publisher","first-page":"521","DOI":"10.21873\/cgp.20277","volume":"18","author":"S Kuramitsu","year":"2021","unstructured":"Kuramitsu S, Masuda T, Hu Q, Tobo T, Yashiro M, Fujii A, et al. Cancer-associated fibroblast-derived spondin-2 promotes motility of gastric cancer cells. Cancer Genomics Proteomics. 2021;18(4):521\u20139. https:\/\/doi.org\/10.21873\/cgp.20277.","journal-title":"Cancer Genomics Proteomics"},{"key":"2075_CR169","doi-asserted-by":"publisher","unstructured":"Zheng H, Liu H, Li H, Dou W, Wang X. Weighted gene Co-Expression network analysis identifies a cancer-Associated fibroblast signature for predicting prognosis and therapeutic responses in gastric cancer. Front Mol Biosci 2021 Oct 8:8744677. https:\/\/doi.org\/10.3389\/fmolb.2021.744677","DOI":"10.3389\/fmolb.2021.744677"},{"issue":"1","key":"2075_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, Wang Z, Xun Z, et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1\u2009+\u2009macrophages in colorectal cancer. Nat Commun. 2022;13(1):1742. https:\/\/doi.org\/10.1038\/s41467-022-29366-6.","journal-title":"Nat Commun"},{"issue":"1","key":"2075_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34395-2","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Xia X, Huang L, An H, Cao M, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619. https:\/\/doi.org\/10.1038\/s41467-022-34395-2.","journal-title":"Nat Commun"},{"issue":"4","key":"2075_CR172","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, Liang S, Li X, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78(4):770\u201382. https:\/\/doi.org\/10.1016\/j.jhep.2023.01.011.","journal-title":"J Hepatol"},{"issue":"7517","key":"2075_CR173","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):11\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"issue":"11","key":"2075_CR174","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","volume":"40","author":"C Ma","year":"2016","unstructured":"Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. Am J Surg Pathol. 2016;40(11):1496\u2013506. https:\/\/doi.org\/10.1097\/PAS.0000000000000698.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2075_CR175","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-017-0454-7","volume":"10","author":"ZW Myint","year":"2017","unstructured":"Myint ZW, Goel G. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol. 2017;10(1):86. https:\/\/doi.org\/10.1186\/s13045-017-0454-7.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2075_CR176","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.yexcr.2017.08.028","volume":"359","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Du W, Chen Z, Xiang C. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Exp Cell Res. 2017;359(2):449\u201357. https:\/\/doi.org\/10.1016\/j.yexcr.2017.08.028.","journal-title":"Exp Cell Res"},{"issue":"20","key":"2075_CR177","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/1759-7714.14108","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Liu H, Zhao Y, Yue D, Chen C, Li C, et al. Tumor-Associated Macrophages (TAMs)-Derived Osteopontin (OPN) Upregulates PD-L1 Expression and Predicts Poor Prognosis in non-Small Cell Lung Cancer (NSCLC). Thorac Cancer. 2021;12(20):2698\u2013709. https:\/\/doi.org\/10.1111\/1759-7714.14108.","journal-title":"Thorac Cancer"},{"issue":"7693","key":"2075_CR178","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. Tgf\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"issue":"389","key":"2075_CR179","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017;9(389):eaal3604. https:\/\/doi.org\/10.1126\/scitranslmed.aal3604.","journal-title":"Sci Transl Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02075-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:02:57Z","timestamp":1771336977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02075-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2075"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02075-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest regarding thepublication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"157"}}